AllDocs -> cancers

C L I N I C A L & H E A L T H A F F A I R S Table 1 Demographics for People with Brain Metastases from Lung Cancer : Olmsted County, Minnesota, 1988–2000 Men Women n=69 n=69 Age at diagnosis 62.6 years 63.4 years Years from diagnosis 0.9 years 0.6 years to brain metastases Stage/Grade Stage III or IV (T3 or T4) 51 (74%) 59 (85%) Grade 3 or 4 61 (88%) 65 (94%) Cell type Small cell 20 (29%) 19 (28%) Large cell 7 (10%) 1 ( 1%) Adenocarcinoma 28 (41%) 28 (41%) Squamous 7 (10%) 11 (16%) Other 7 (10%) 10 (14%) 1988–1990 1991–1993 1994–1996 1997–1999 Figure Cases of Brain Metastasis as a Proportion of Cases of Primary Cancer : Olmsted County, Minnesota, 1988–2000 *Cases diagnosed at autopsy are excluded. ...

Media Contact: Sandra Van Telephone: 1-800-880-2397 E-mail: sandy@vancommunications.com Oct. 1, 2003 – FOR IMMEDIATE RELEASE POSSIBLE BRAIN CANCER -AIR POLLUTION LINK TO BE STUDIED By Internationally Renowned Neurosurgeon and AQMD Foundation LOS ANGELES, CA (Oct. 1, 2003 – The Brain Tumor and Air Pollution Foundation today announced the beginning of a research project led by an internationally renowned neurosurgeon at Cedars-Sinai Medical Center to explore a possible link between brain cancer and air pollution. The study will be led by Keith Black, M.D., director of the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Division of Neurosurgery in Los Angeles. The Brain Tumor foundation recently awarded $559,250 to the research project, with funding from the South Coast Air Quality Management District (AQMD). The Cedars-Sinai investigation will examine biochemical and ...

Berkshire Priorities Committee Policy Statement 39 Temozolomide for Brain Cancer Date of Issue August 2001 Review Date March 2004 Malignant glioma is the most common form of primary brain cancer in England and Wales (about 3,500 patients each year) but accounts for less than 1% of all cancers. In Berkshire this is approximately 10-12 patients; patients currently receive supportive care with steroids and or anticonvulsants. The National Institute of Clinical Excellence (NICE) reviewed the one RCT available comparing Temozolomide with procarbazine (225 patients); progression free survival at six months was 21% Vs 8%. However, the median survival advantage was six weeks and not deemed statistically significant. The cost effectiveness of Temozolomide was not considered due to the limited clinical effectiveness evidence available. NICE recommends ...

W F R I E N D S F O R L I F E MARCH-APRIL 2004 6 VOLUME SIX 3202 North Meridian Street Indianapolis, IN 46208 • Joseph E. Walther, M.D. President / CEO Emeritus • Visit our web site at www.walther.org Nonprofit Organization U.S. Postage PAID Indianapolis, IN Permit No. 399 Eliminating cancer as a cause of suffering and death Walther Cancer Institute Eliminating Cancer as a Cause of Suffering and Death There have long been behavioral studies examining the effects of provid- ing care on caregivers of persons with cancer . There have also been many studies researching the effects of caring for someone debilitated by demen- tia or brain injury. However, few studies exist to study the relationship between the two. What happens to the caregiver ...

Brochure More information from http://www.researchandmarkets.com/reports/6158 Medicines in Development for Brain Cancer Description: Database Table: Medicines in Development for Brain Cancer Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology and healthcare sectors. Over 600 database tables are now available from Research and Markets A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: ...

MEDIGENE RECEIVES ORPHAN DRUG STATUS FOR ITS BRAIN CANCER DRUG CANDIDATE G207 Seven Years Marketing Exclusivity after FDA Approval for G207 – Tax Benefits on Clinical Research and Development Costs – Clinical Protocol Assistance from the Office of Orphan Products Development Martinsried/San Diego, May 8, 2002. The German-American biopharmaceutical company MediGene (NMarkt: MDG) announced today that the Office of Orphan Products Development (OOPD) of the United States Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate G207 for the treatment of malignant glioma, one of the most aggressive brain tumors in man. Orphan drug designation allows MediGene exclusive marketing rights for G207 in the US for seven years following marketing approval by the FDA. The designation also enables MediGene to apply for clinical research funding, tax credits on clinical ...

Abstract. Although conventional chemotherapies are used to treat patients with malignancies, damage to normal cells is problematic. Blood-forming bone marrow cells are the most adversely affected. It is therefore necessary to find alternative agents that can kill cancer cells but have minimal effects on normal cells. We investigated the brain cancer cell-killing activity of a homeopathic medicine, Ruta, isolated from a plant, Ruta graveolens . We treated human brain cancer and HL-60 leukemia cells, normal B-lymphoid cells, and murine melanoma cells in vitro with different concentrations of Ruta in combination with Ca 3 (PO 4 ) 2 . Fifteen patients diagnosed with intracranial tumors were treated with Ruta 6 and Ca 3 (PO 4 ) 2 . Of these 15 patients, 6 of the 7 glioma patients ...

CANCER of the BRAIN and OTHER NERVOUS SYSTEM Pennsylvania Department of Health - Pennsylvania Cancer Incidence and Mortality 1993-1997 - Page 164 While some cases show an autosomal dominant pattern, no genetic factor has been found to influence the overall incidence of primary nervous system tumors. Etiological factors are obscure. Risk Factors FIGURE 19 Average Annual Age-Adjusted Incidence and Mortality Rates* by Sex and Race, Pennsylvania Residents, 1993-1997 None proven to be effective or currently being evaluated. Early Detection *per 100,000 1970 U.S. standard million population. During 1997, there were 896 cases of primary brain and other central nervous system cancers reported to the Pennsylvania Cancer Registry. This was the highest annual number recorded between 1988 and 1997. The average annual (1993-97) age-adjusted incidence rates ...

Joanne's Story: Losing Her Partner to Brain Cancer Dr. Ronit Elk: Hello and welcome to the American Cancer Society Cancer Survivors Network®. My name is Dr. Ronit Elk, and I will be your host today. I will be talking one-on- one with women whose partners had cancer , but unfortunately they have passed away. I myself have been a caregiver for three of my very close family members, all of whom died of cancer , and so I am especially pleased to speak to our guests about these very difficult issues and major challenges. We will talk about what it is like to be a caregiver, like what were some of the most difficult challenges and how this affected this relationship. We will also touch on communication, especially the most difficult issue, I think for most people, which is talking about coming to the end of life. I'd ...

188 N ORTHERN C ALIFORNIA C ANCER C ENTER , Cancer Incidence and Mortality in the Greater San Francisco Bay Area Brain and Other Nervous System Cancer TABLE 1. Brain and Other Nervous System Cancer . Annual Death Counts, Age-Adjusted Mortality Rates per 100,000 Population, a and 95% Confidence Intervals (CI), by Sex and Race/Ethnicity, 1988-2000, Greater San Francisco Bay Area b TOTAL MALES FEMALES Year Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI ALL RACES 1988-1993 c 1,405 4.4 4.2-4.7 792 5.5 5.1-5.9 613 3.5 3.3-3.8 1994 230 4.1 3.5-4.6 133 5.0 4.2-6.0 97 ...

C LINICAL J OURNAL OF O NCOLOGY N URSING • V OLUME 7, N UMBER 2 • N EWS B RIEFS 135 N EWS B RIEFS D IANE C OPE , P H D, ARNP-BC, AOCN ® A SSOCIATE E DITOR Digital Object Identifier: 10.1188/03.CJON.135-136 Book About Dog’s Brain Tumor Encourages Children With Cancer A book about a dog’s account of his ex- perience with a cancerous brain tumor is de- signed to help children with the disease. Buddy, a nine-year-old golden retriever, “wrote” (with the help of his owner, Dave Bauer, and the National Brain Tumor Foun- dation [NBTF]) My Name Is Buddy, a children’s book about his diagnosis, ...

IN VIVO STUDY OF GADOLINIUM UPTAKE BY BRAIN CANCER L. M. Wiese a , B. H. Frazer a,b , B. R. Sonderegger a , B. Gilbert c , K. L. Richter d , P. Casalbore e , L. M. Larocca f , R. Pallini f , and G. De Stasio a a) Dept. of Physics and Synchrotron Radiation Center, University of Wisconsin at Madison. b) Institute de Physique Appliquée, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. c) Dept. of Earth and Planetary Sciences, University of California Berkeley. d) Bob Jones University, South Carolina. e) Istituto di Neurobiologia e Medicina Molecolare, CNR, Rome, Italy f) Catholic University of Rome and Policlinico Gemelli, Rome, Italy Gadolinium is a new potential agent for neutron capture ...

This factsheet is for those who have been diagnosed with secondary cancer in the brain that has spread from the breast. It describes what secondary brain cancer is, what the symptoms are and the treatments used. We hope it answers some of your questions and helps you to discuss your options with your specialist. Being told that your cancer has spread to the brain can be particularly distressing and one of the common fears people have is of not knowing what effects this will have on their life. You may find it helpful to read our booklet about secondary breast cancer , which also looks at the emotional impact of the disease. What is secondary brain cancer ? Secondary brain cancer occurs when cancer cells from the breast spread through the blood stream to the brain . This may be described as metastases, recurrent breast cancer , a secondary tumour or secondaries. ...

Secondary brain cancer This factsheet is for those who have been diagnosed with secondary cancer in the brain that has spread from the breast. It describes what secondary brain cancer is, what the symptoms are and the treatments used. We hope it answers some of your questions and helps you to discuss your options with your specialist. Being told that your cancer has spread to the brain can be particularly distressing and one of the common fears people have is of not knowing what effects this will have on their life. You may find it helpful to read our booklet about secondary breast cancer , which also looks at the emotional impact of the disease. What is secondary brain cancer ? Secondary brain cancer occurs when cancer cells from the breast spread through the blood stream to the brain . This may be described as metastases, recurrent ...

The Blood- Brain Barrier, Cancer , Cell Phones, and Microwave Radiation I James C. Lin A n important announcement was made on 22 May 2001. A five-year study by the U.S. Na- tional Toxicology Program (NTP), lo- cated at Research Triangle Park, N.C., will focus on whether microwave radia- tion from cellular mobile telephones causes cancer . “With over one billion cell phones in use worldwide, it is criti- cal to obtain scientifically rigorous labo- ratory studies of the potential for health effects from long-term use of these products,” said Kenneth Olden, head of the National Institute of Environmental Health Sciences (NIEHS) and director of the NTP. NIEHS is an arm of the Na- tional Institutes of Health (NIH), based in Washington, D.C. The NTP will be doing the studies at the request of the U.S. Food and Drug Administration (FDA), ...

Inhibition of breast and brain cancer cell growth by BCCIPa, an evolutionarily conserved nuclear protein that interacts with BRCA2 Jingmei Liu 1 , Yuan Yuan 1,2 , Juan Huan 2 and Zhiyuan Shen* ,1 1 Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center; 915 Camino de Salud, NE. Albuquerque, New Mexico, NM 87131, USA; 2 Graduate Program of Molecular Genetics, College of Medicine, University of Illinois at Chicago, 900 S. Ashland Ave. Chicago, Illinois, IL 60607, USA BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis. Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14 ± 24. We identi®ed a novel protein, designated BCCIPa, that interacts with part ...

A221: Brain cancer tissues: Glioblastoma For research use only (formalin fixed) Specifications: • No. of cases: 30 • Tissue type: Brain cancer tissues: Glioblastoma • No. of spots: 2 spots from each cancer case (60 spots) 2 non-neoplastic spots (2 spots) • Total spots: 62 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A221: Brain cancer tissues: Glioblastoma For research use only (formalin fixed) Summary of tissue spots No. Sex Age Key Word 1 1, 2 f 68 glioblastoma 2 3, 4 f 67 glioblastoma 3 5, 6 m ...

APPENDIX A SECTION 1. SHORT TITLE. This Act may be cited as the `Benign Brain Tumor Cancer Registries Amendment Act'. SEC. 2. NATIONAL PROGRAM OF CANCER REGISTRIES; BENIGN BRAIN - RELATED TUMORS AS ADDITIONAL CATEGORY OF DATA COLLECTED. (a) IN GENERAL- Section 399B of the Public Health Service Act (42 U.S.C. 280e), as redesignated by section 502(2)(A) of Public Law 106-310 (114 Stat. 1115), is amended in subsection (a)-- (1) by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively, and indenting appropriately; (2) by striking `(a) IN GENERAL- The Secretary' and inserting the following: `(a) IN GENERAL- `(1) STATEWIDE CANCER REGISTRIES- The Secretary'; (3) in the matter preceding subparagraph (A) (as so redesignated), by striking `population-based' and all that follows through `data' and inserting the following: `population-based, ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health August, 2001 Brain Cancer Brain tumors can be either malignant (cancerous) or benign (non-cancerous). Primary brain tumors (i.e., brain cancer ) comprise two main types: gliomas and malignant meningiomas. Gliomas are a general classification of malignant tumors that include a variety of types, named for the cells from which they arise: astrocytomas, oligodendrogliomas, and ependymomas. Meningiomas arise from the meninges, which are tissues that surround the outer part of the spinal cord and brain . Although meningiomas are not technically brain tumors, as they occur outside of the brain , they account for about 50% of all reported primary brain and spinal cord tumors. The majority of meningiomas (about ...

brain cancer Leukemia Leukemia is the general term that includes a group of different cancers that occur in the blood forming organs and result in the formation of abnormal amounts and types of white blood cells in the blood and bone marrow. Individuals with leukemia generally maintain abnormally high amounts of leukocytes or white blood cells in their blood. This condition results in an individual?s inability to maintain certain body functions, particularly a person?s ability to combat infection. In 2002, leukemia is expected to affect approximately 30,800 individuals (17,600 males and 13,200 females) in the United States, resulting in 21,700 deaths. In Massachusetts, approximately 700 individuals will be diagnosed with the disease in 2002, representing more than 2% of all cancer diagnoses. There are four major types of leukemia: acute lymphoid leukemia (ALL), acute myeloid leukemia ...

Total Male Female 1982-1992 Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI Ashfield 11 7.6 144 72—259 5 3.9 127 41—299 6 3.7 162 59--353 Buckland 3 1.4 NC NC 2 0.7 NC NC 1 0.6 NC NC Charlemont 0 0.9 NC NC 0 0.5 NC NC 0 0.4 NC NC Conway 1 1.0 NC NC 1 0.5 NC NC 0 0.5 NC NC Deerfield 7 3.7 189 76—389 3 1.9 NC NC 4 1.8 NC NC Florida 2 0.5 NC NC 0 0.3 NC NC 2 0.2 NC NC Hawley 0 0.3 NC NC 0 0.1 NC NC 0 0.1 NC NC ...

Massachusetts Department Of Public Health Bureau of Environmental Health Assessment, Community Assessment Program Assessment of Brain and Central Nervous System Cancer Incidence in Needham, MA 1987-1998 December, 2002 Page 2 Assessment of Brain and Central Nervous System Cancer Incidence in Needham, MA 1987-1998 T ABLE OF C ONTENTS I. INTRODUCTION .1 II. OBJECTIVES1 III. METHODS FOR ANALYZING CANCER INCIDENCE 3 A. Case Identification.3 B. Calculation of Standardized Incidence Ratios (SIRs)..3 C. Calculation of 95% Confidence Interval 5 D. Evaluation of Risk Factor Information 6 E. Determination of Geographic Distribution 6 IV. METHODS FOR ASSESSING ENVIRONMENTAL ...

SEARCH Recommended Search Terms Advanced Search HOT LISTS: Readers' Favorites Best-Seller List Science & Technology Web Awards December 10, 2003 ADVERTISEMENT December 08, 2003 Modified Poliovirus Targets Brain Cancer Cells Under normal circumstances, being injected with the poliovirus would be considered a bad thing. But for a patient suffering from brain cancer , that could one day be an effective means of treating the disease. A modified form of polio has been tested in monkeys and kills cancer cells while leaving healthy neurons untouched. Now scientists writing in the December 9 issue of the have shed light on the mechanism behind this selectivity. Proceedings of the National Academy of Sciences In the emerging field of virotherapy, researchers genetically engineer ...

SPECIMEN Blankshire Cancer Network: Suspected Brain Tumour Referral Form To make a referral, FAX this form to the Urgent Referral Team at the relevant hospital. If you wish to send an accompanying letter, please do so Please corresponding box for which hospital referred to: Hospital A: fax: tel: Hospital C: fax: tel: Hospital E: fax: tel: Hospital B: fax: tel: Hospital D: fax: tel: Hospital F: fax: tel: From: (use practice stamp if available): Address: .. Post code: .. Date of Referral: ./../ GP’s name: . P.C.G. code:.. Tel no: Fax no. .. Patient Details: Name: . Address: . Post code: . Has the patient previously visited this hospital? Y / N Interpreter required? Y / N D.O.B: / ../ Age: Gender: m/ f Tel no (home): Tel no (work): . New NHS No:. ...

Cancer Therapy Vol 2, page 21 21 Cancer Therapy Vol 2, 21-26, 2004 Cancer vaccine for brain tumors and brain tumor antigens Review Article Masahiro Toda Department of Neurosurgery and Neuro-immunology Research Group, Keio University School of Medicine, Tokyo, Japan _ *Correspondence: Masahiro Toda, MD, PhD, Department of Neurosurgery and Neuro-immunology Research Group, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; e-mail: todam@sc.itc.keio.ac.jp Key Words: glioma, CNS, HSV, G207, DC, tumor antigen Abbreviations: antigen-presenting cells, (APCs); blood- brain barrier, (BBB); Cancer -testis, (CT); central nervous system, (CNS); cytotoxic T lymphocytes, (CTLs); dendritic cells, (DCs); herpes simplex virus type-1, (HSV-1); high mobility group, (HMG); major histocompatibility complex, (MHC); natural killer, ...

Rachel's Environment & Health News #266 - Brain Cancer Is Rapidly Increasing December 31, 1991 Brain cancer is relatively rare, accounting for only 2% of all cancers, but it seems to be increasing rapidly in children and in people over 65 in the U.S. The latest figures from the National Cancer Institute indicate that brain cancer in the elderly (ages 75-84) is doubling every 9 years [1, pg. 1621; 2, pg. 635.] In 1991 in the U.S., an estimated 16,700 new cases of brain cancer were diagnosed and an estimated 11,500 deaths occurred. [3, pgs. I.15-I.16] The causes of brain cancer are unknown. Brain cancer is usually fatal; the average (median) time between diagnosis and death is about nine months. [1, pg. 1621.] The average survival rate after 5 years is 25%, but in people over 65 the 5-year survival rate is only 4%. [3, pg. I.16.] ...